Zidovudine Genotypic Resistance in HIV-1-Infected Newborns in the French Perinatal Cohort

A retrospective study was set up to investigate the frequency of zidovudine (ZDV)-resistant HIV-1 in infected newborns after ZDV prophylaxis in the French Perinatal Cohort study.Nucleotide sequence analysis was carried out from 34 infants' isolates and 18 maternal plasma samples. Mutations rela...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of acquired immune deficiency syndromes (1999) 2001-06, Vol.27 (2), p.99-104
Hauptverfasser:	Masquelier, Bernard, Chaix, Marie-Laure, Burgard, Marianne, Lechenadec, Jérome, Doussin, Anne, Simon, François, Cottalorda, Jacqueline, Izopet, Jacques, Tamalet, Catherine, Douard, Danielle, Fleury, Hervé, Mayaux, Marie-Jeanne, Blanche, Stéphane, Rouzioux, Christine
Format:	Artikel
Sprache:	eng
Schlagworte:	AIDS/HIV Anti-HIV Agents - pharmacology Anti-HIV Agents - therapeutic use Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral agents Babies Biological and medical sciences Cohort Studies Drug resistance Drug Resistance, Microbial - genetics Drugs Experimental viral diseases and models Female France Fundamental and applied biological sciences. Psychology HIV HIV Infections - prevention & control HIV Infections - virology HIV Reverse Transcriptase - genetics HIV-1 - classification HIV-1 - drug effects HIV-1 - genetics Human immunodeficiency virus Human immunodeficiency virus 1 Humans Infant, Newborn Infectious Disease Transmission, Vertical - prevention & control Infectious diseases Medical sciences Microbiology Molecular Sequence Data Pharmacology. Drug treatments Pregnancy Pregnancy Complications, Infectious - virology Retrospective Studies Reverse Transcriptase Inhibitors - pharmacology Reverse Transcriptase Inhibitors - therapeutic use RNA, Viral - blood Viral diseases Zidovudine - pharmacology Zidovudine - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!